XieYi Lanzhou: The balance between the quality and cost of biological drugs

The biopharmaceutical industry has been developing worldwide since the 1980’s. Between 2005 and 2017, the industry experienced massive growth as biologics became the largest market in North America and the fastest growing market in Asia. It is expected to nearly double by the end of the decade. A dramatic increase in the demand for high quality and affordable cell culture media will accompany this market growth as biologics have become the dominant focus area within research and development. In recent years, topics of focus receiving special attention in this area include bispecific antibodies, antibody-drug conjugates (ADCs), and cell and gene therapy. Public and private biopharmaceutical drug development companies are both in favor of market capital as immunotherapies offer safer and more personalized treatments for disease.

In September, at the company’s Lanzhou facility, the original home of Jianshun Biosciences (JSBio) and Thousand Oaks Biologics (TOBio), we hosted a summit for leaders in the fields of immunotherapy and biomanufacturing from all over China. The purpose of the meeting was to provide an opportunity for key players in the industry to have a panel discussion addressing current topics in the industry and the rising demands for cell culture media and process development. Equally as important, was the need to develop plans to improve production efficiency in a cost effective manner as the future demand for biologics production continues to grow up rapidly. JSBio continues to expand internationally in the interest of providing cell culture media (JSBio) and CDMO services (TOBio) to a global clientele. JSBio and TOBio are on a mission to provide cost effective and quality products and services to domestic and global markets. Our mission is to provide more accessible and affordable high quality biologics for patients all over the world.


At its original cell culture media manufacturing facility in Lanzhou, JSBio hosted a bioprocessing summit for experts in biomanufacturing from all over China. This meeting was held to bring together industry leaders to discuss the most efficient ways to navigate current challenges in the manufacturing of biologics as the demand continues to soar. Chairman and President of JSBio and TOBio, Shun Luo, leads the group on a tour of the production facility and the R&D laboratories located at Lanzhou site prior to kicking off the discussion panel.


Experts in immunology and the biopharmaceutical industry from all over China united to participate in the bioprocessing summit held at JSBio’s Lanzhou site. With all hands on deck, we discussed the current ecosystem as well as the most efficient ways to handle a rapidly growing demand for process development and production of immunotherapies.